The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia
详细信息 查看全文
- 作者：Alexandra McFarlane ; Wendy Sligl
- 关键词：Macrolide ; based regimens ; Community ; acquired pneumonia ; Macrolide antimicrobials ; Respiratory tract infections
- 刊名：Current Infectious Disease Reports
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：17
- 期：12
- 全文大小：963 KB
- 参考文献：1.Schlunzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413(6858):814鈥?1. doi:10.鈥?038/鈥?5101544 .CrossRef PubMed
2.Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003;330(5):1005鈥?4.CrossRef PubMed
3.Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987;31(12):1939鈥?7.PubMed Central CrossRef PubMed
4.Drew RH, Gallis HA. Azithromycin鈥攕pectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy. 1992;12(3):161鈥?3.PubMed
5.Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44(5):750鈥?9.CrossRef PubMed
6.Georgopapadakou NH. The wobbly status of ketolides: where do we stand? Expert Opin Investig Drugs. 2014;23(10):1313鈥?. doi:10.鈥?517/鈥?3543784.鈥?014.鈥?54036 .CrossRef PubMed
7.Ross DB. The FDA, and the case of Ketek. N Engl J Med. 2007;356(16):1601鈥?.CrossRef PubMed
8.Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56(3):1418鈥?6. doi:10.鈥?128/鈥婣AC.鈥?5658-11 .PubMed Central CrossRef PubMed
9.Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005;41(2):139鈥?8.CrossRef PubMed
10.Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE ceftaroline surveillance program (2008鈥?010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55 Suppl 3:S187鈥?3. doi:10.鈥?093/鈥媍id/鈥媍is561 .CrossRef PubMed
11.Adam HJ, Baxter MR, Davidson RJ, et al. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013;68 Suppl 1:i31鈥?. doi:10.鈥?093/鈥媕ac/鈥媎kt024 .CrossRef PubMed
12.Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160鈥?. doi:10.鈥?128/鈥婣AC.鈥?1684-08 .PubMed Central CrossRef PubMed
13.Diaz MH, Benitez AJ, Winchell JM. Investigations of mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53(1):124鈥?0. doi:10.鈥?128/鈥婮CM.鈥?2597-14 .PubMed Central CrossRef PubMed
14.Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40(9):1288鈥?7.CrossRef PubMed
15.Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med. 2015;191(11):1265鈥?2. doi:10.鈥?164/鈥媟ccm.鈥?01502-0212OC .CrossRef PubMed
16.Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286(15):1857鈥?2.CrossRef PubMed
17.Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16(3):217鈥?5. doi:10.鈥?097/鈥婱CP.鈥?b013e3283385653鈥?/span> .PubMed
18.Barnes DM, Whittier S, Gilligan PH, Soares S, Tomasz A, Henderson FW. Transmission of multidrug-resistant serotype 23F streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis. 1995;171(4):890鈥?.CrossRef PubMed
19.Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis. 1995;20(4):826鈥?5.CrossRef PubMed
20.Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007;44 Suppl 2:S27鈥?2. doi:10.鈥?086/鈥?11159 .CrossRef PubMed
21.Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis. 2003;36(9):1132鈥?.CrossRef PubMed
22.Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents. 2001;18 Suppl 1:S3鈥?0.CrossRef PubMed
23.Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996;40(8):1817鈥?4.PubMed Central PubMed
24.Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis. 2005;11(6):851鈥?. doi:10.鈥?201/鈥媏id1106.鈥?50222 .PubMed Central CrossRef PubMed
25.Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68(5):479鈥?03. doi:10.鈥?007/鈥媠00228-011-1161-x .CrossRef PubMed
26.Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97(7):844鈥?0.CrossRef PubMed
27.Gaylor AS, Reilly JC. Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy. 2002;22(2):227鈥?9.CrossRef PubMed
28.Zhuo GY, He Q, Xiang-Lian L, Ya-Nan Y, Si-Te F. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Pulm Pharmacol Ther. 2014;29(1):80鈥?. doi:10.鈥?016/鈥媕.鈥媝upt.鈥?014.鈥?2.鈥?02 .CrossRef PubMed
29.Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1):36鈥?1. doi:10.鈥?097/鈥?1.鈥媡p.鈥?000295981.鈥?4633.鈥媌c .CrossRef PubMed
30.Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322鈥?. doi:10.鈥?136/鈥媡horaxjnl-2012-202698 .CrossRef PubMed
31.Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):e0121257. doi:10.鈥?371/鈥媕ournal.鈥媝one.鈥?121257 .PubMed Central CrossRef PubMed
32.Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs. 2000;1(2):169鈥?2.PubMed
33.Suzuki H, Shimomura A, Ikeda K, Furukawa M, Oshima T, Takasaka T. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope. 1997;107(12 Pt 1):1661鈥?.CrossRef PubMed
34.Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J. 1995;8(9):1451鈥?.PubMed
35.Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation. 1996;20(6):693鈥?05.CrossRef PubMed
36.Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother. 2004;48(5):1581鈥?.PubMed Central CrossRef PubMed
37.Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995;39(4):872鈥?.PubMed Central CrossRef PubMed
38.Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med. 2003;168(5):581鈥?. doi:10.鈥?164/鈥媟ccm.鈥?00212-1437OC .CrossRef PubMed
39.Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117(3):393鈥?05. doi:10.鈥?016/鈥媕.鈥媝harmthera.鈥?007.鈥?1.鈥?01 .CrossRef PubMed
40.Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46(8):1157鈥?4. doi:10.鈥?086/鈥?29439 .CrossRef PubMed
41.Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother. 2012;56(7):3819鈥?5.PubMed Central CrossRef PubMed
42.Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine. 2013;31(42):4881鈥?. doi:10.鈥?016/鈥媕.鈥媣accine.鈥?013.鈥?7.鈥?54 .CrossRef PubMed
43.Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med. 2012;106(3):451鈥?.CrossRef PubMed
44.Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2013;19(4):370鈥?.CrossRef PubMed
45.Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2014;10:CD002109. doi:10.鈥?002/鈥?4651858.鈥婥D002109.鈥媝ub4 .PubMed
46.Laopaiboon M, Panpanich R, Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev. 2015;3:CD001954. doi:10.鈥?002/鈥?4651858.鈥婥D001954.鈥媝ub4 .PubMed
47.Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117(5 Suppl 2):380S鈥?.CrossRef PubMed
48.Boldy DA, Skidmore SJ, Ayres JG. Acute bronchitis in the community: clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine. Respir Med. 1990;84(5):377鈥?5.CrossRef PubMed
49.Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Emerg Med. 2001;37(6):720鈥?.CrossRef PubMed
50.Lynch III JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis. 2002;34 Suppl 1:S27鈥?6.CrossRef
51.Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159(21):2562鈥?2.CrossRef PubMed
52.Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119(5):1420鈥?.CrossRef PubMed
53.Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000;34(4):446鈥?2.CrossRef PubMed
54.Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123(5):1503鈥?1.CrossRef PubMed
55.Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections鈥攆ull version. Clin Microbiol Infect. 2011;17 Suppl 6:E1鈥?9. doi:10.鈥?111/鈥媕.鈥?469-0691.鈥?011.鈥?3672.鈥媥 .CrossRef PubMed
56.Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2005;2(2):CD004418. doi:10.鈥?002/鈥?4651858.鈥婥D004418.鈥媝ub2 .PubMed
57.Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005;330(7489):456.PubMed Central CrossRef PubMed
58.Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2012;9:004418.
59.Nie W, Li B, Xiu Q. Beta-lactam/macrolide dual therapy versus beta-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(6):1441鈥?.CrossRef PubMed
60.Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312鈥?3.CrossRef PubMed
61.Garin N, Genne D, Carballo S, et al. Beta-lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894鈥?01.CrossRef PubMed
62.Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Impact of guideline-concordant antibiotics and macrolide/beta-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect. 2013;19(3):257鈥?4.CrossRef PubMed
63.Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55(3):371鈥?0.CrossRef PubMed
64.Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000;162(1):154鈥?0. doi:10.鈥?164/鈥媋jrccm.鈥?62.鈥?.鈥?907023 .CrossRef PubMed
65.Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164(5):502鈥?. doi:10.鈥?001/鈥媋rchinte.鈥?64.鈥?.鈥?02 .CrossRef PubMed
66.Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462鈥?4.CrossRef PubMed
67.Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420鈥?2.CrossRef PubMed
68.Adrie C, Schwebel C, Garrouste-Orgeas M, et al. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit Care. 2013;17(6):R265. doi:10.鈥?186/鈥媍c13095 .PubMed Central CrossRef PubMed
69.Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612鈥?0. doi:10.鈥?007/鈥媠00134-009-1730-y .CrossRef PubMed
70.Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153鈥?. doi:10.鈥?183/鈥?9031936.鈥?0054108 .CrossRef PubMed
71.Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131(2):466鈥?3. doi:10.鈥?378/鈥媍hest.鈥?6-1426 .CrossRef PubMed
72.Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36(4):389鈥?5.CrossRef PubMed
73.Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(12):1269鈥?7. doi:10.鈥?503/鈥媍maj.鈥?80358; 10.鈥?503/鈥媍maj.鈥?80358 .PubMed Central CrossRef PubMed
74.Lode H, File Jr TM, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther. 2002;24(11):1915鈥?6.CrossRef PubMed
75.Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P, MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41(12):1697鈥?05.CrossRef PubMed
76.Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004;98(8):708鈥?0.CrossRef PubMed
77.Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med. 2007;167(15):1655鈥?3.PubMed Central CrossRef PubMed
78.Kovaleva A, Remmelts HH, Rijkers GT, Hoepelman AI, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother. 2012;67(3):530鈥?0.CrossRef PubMed
79.Albert RK, Schuller JL, Clinical Research Network COPD. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med. 2014;189(10):1173鈥?0. doi:10.鈥?164/鈥媟ccm.鈥?01402-0385CI .PubMed Central CrossRef PubMed
80.Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014;32(1):19鈥?5. doi:10.鈥?111/鈥?755-5922.鈥?2054 .CrossRef PubMed
81.Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12):1603鈥?1.CrossRef PubMed
82.Howard PA. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother. 2013;47(11):1547鈥?1. doi:10.鈥?177/鈥?060028013504905鈥?/span> .CrossRef PubMed
83.Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704鈥?2. doi:10.鈥?056/鈥婲EJMoa1300799 .CrossRef PubMed
84.Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881鈥?0. doi:10.鈥?056/鈥婲EJMoa1003833 .PubMed Central CrossRef PubMed
85.Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311(21):2199鈥?08.PubMed Central CrossRef PubMed - 作者单位：Alexandra McFarlane (1)
Wendy Sligl (2)
1. Division of Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, 1-124 Clinical Sciences Building, 8440 112 Street, Edmonton, AB, T6G 2B7, Canada
2. Divisions of Critical Care Medicine and Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440 112 Street, Edmonton, AB, T6G 2B7, Canada - 刊物主题：Infectious Diseases;
- 出版者：Springer US
- ISSN：1534-3146
文摘
Macrolide antimicrobials are commonly prescribed, specifically for the treatment of respiratory tract infections. Although still effective, the development of widespread macrolide resistance has limited their use. Aside from their antimicrobial effects, macrolides are also known to possess immune-modulatory properties which may confer a survival benefit in both acute and chronic inflammatory states. This review discusses the efficacy, potential mechanisms, and adverse effects of macrolide therapy specifically in community-acquired pneumonia in outpatients, hospitalized ward patients, and those requiring intensive care unit admission. Challenges for ongoing research in this field are discussed and treatment recommendations offered. Keywords Macrolide-based regimens Community-acquired pneumonia Macrolide antimicrobials Respiratory tract infections